DZ Bank Reiterates “Buy” Rating for Bayer (BAYN)

Bayer (FRA:BAYN)‘s stock had its “buy” rating restated by DZ Bank in a report issued on Monday.

Other equities research analysts have also issued reports about the stock. set a €105.00 ($125.00) price target on shares of Bayer and gave the company a “neutral” rating in a report on Wednesday, August 23rd. Jefferies Group set a €137.00 ($163.10) price objective on shares of Bayer and gave the stock a “buy” rating in a research report on Wednesday, August 23rd. Warburg Research set a €121.00 ($144.05) target price on shares of Bayer and gave the company a “buy” rating in a report on Wednesday, August 23rd. Independent Research set a €120.00 ($142.86) target price on shares of Bayer and gave the company a “neutral” rating in a report on Wednesday, August 23rd. Finally, UBS set a €125.00 ($148.81) target price on shares of Bayer and gave the company a “buy” rating in a report on Wednesday, August 23rd. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and fourteen have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of €122.19 ($145.46).

Shares of Bayer (FRA:BAYN) opened at €105.05 ($125.06) on Monday. Bayer has a 12 month low of €90.26 ($107.45) and a 12 month high of €123.82 ($147.40).

ILLEGAL ACTIVITY NOTICE: “DZ Bank Reiterates “Buy” Rating for Bayer (BAYN)” was originally posted by Transcript Daily and is owned by of Transcript Daily. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark law. The legal version of this piece of content can be accessed at https://transcriptdaily.com/2017/12/11/dz-bank-reiterates-buy-rating-for-bayer-bayn.html.

Bayer Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply